Navigation Links
A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe
Date:2/17/2009

A Therapy's Effect on Executive Function and Functional Capacity are the Attributes that Most Influence Psychiatrists' Prescribing Habits, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if a drug were to receive formal regulatory approval for the treatment of cognitive impairment associated with schizophrenia (CIAS), such an agent could earn up to 50 percent patient share in the United States and up to 33 percent patient share in Europe, according to surveyed U.S. and European psychiatrists.

The new report entitled Cognitive Impairment Associated with Schizophrenia: Emerging Consensus Expected to Define a New Indication as Physicians Await the Launch of the First Approved Drug finds that a therapy's effect on executive function (reasoning and problem solving) and functional capacity (ability to manage daily tasks) are the attributes that most influences psychiatrists' prescribing decisions in CIAS. To date, no drugs are formally approved for CIAS and off-label treatment is sporadic. However, clinical data and the opinions of interviewed thought leaders indicate that the currently-available therapy, modafinil (Cephalon's Provigil), as well as emerging agents from Roche/Memory Pharmaceuticals, Allon Therapeutics, Cephalon and Merck could demonstrate advantages in treating CIAS when compared with donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in this virtually untapped market.

"In rare cases when psychiatrists elect to prescribe off-label therapy for CIAS, such as donepezil, their choice of treatment is based in large part on a drug's proven benefits in other indications in the hopes that CIAS patients will experience similar benefits," said Decision Resources Analyst Jonathan Searles. "However, thanks to evolving consensus about clinical trial design and the most promising drug targets in CIAS, a growing number of developers are investigating novel compounds for the treatment of this new indication."

About the Report

Cognitive Impairment Associated with Schizophrenia: Emerging Consensus Expected to Define a New Indication as Physicians Await the Launch of the First Approved Drug is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources                   Decision Resources, Inc.
    Christopher Comfort                  Elizabeth Marshall
    781-296-2597                         781-296-2563
    ccomfort@dresources.com              emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. i.HUG Foundation Receives International Grant: Hires a School Nurse to Improve Student Health and Learning
2. Emageon Receives Escrowed Funds and Terminates Merger Agreement
3. Children's National Medical Center Trauma Center Receives Highest Verification from American College of Surgeons
4. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
5. Rising Medical Solutions Receives URAC Workers Compensation Utilization Management Accreditation
6. Executive Board Member of National Patient Advocate Foundation, Patient Advocate Foundation Receives National Institutes of Health 2008 Health Disparities Excellence Award
7. Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award
8. Boston Medical Center cardiologist receives Drake Award
9. Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden
10. Blue Cross Receives Disease Management Awards
11. ARKRAY USA Receives FDA Clearance on GLUCOCARD(R) 01-mini Blood Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: